NK cells regulating T cell responses: Mechanisms and outcome

Trends in Immunology

Volumn 36, Issue 1, 2015, Pages 49-58

  Crouse, Josh ^a   Xu, Haifeng C ^b   Lang, Philipp A ^b   Oxenius, Annette ^a  

^a ETH ZURICH   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cytokines; Cytotoxicity; Dendritic cells; Natural killer cells; T cells

Indexed keywords

CYTOKINE; NATURAL KILLER CELL RECEPTOR; LIGAND;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; NATURAL KILLER CELL; PATHOGEN LOAD; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL COMMUNICATION; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM;

ANIMALS; CELL COMMUNICATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; LIGANDS; T-LYMPHOCYTES;

EID: 84919626540     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.11.001     Document Type: Review

References (100)

1. Gregoire C., et al. The trafficking of natural killer cells. Immunol. Rev. 2007, 220:169-182.
2. Smyth M.J., et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2002, 2:850-861.
3. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-5943.
4. Cheng M., et al. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 2013, 10:230-252.
5. Sentman C.L., et al. NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res. 2006, 95:249-292.
6. French A.R., Yokoyama W.M. Natural killer cells and viral infections. Curr. Opin. Immunol. 2003, 15:45-51.
7. Biron C.A., et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
8. Walzer T., et al. Natural-killer cells and dendritic cells: 'l'union fait la force'. Blood 2005, 106:2252-2258.
9. Yokoyama W.M., Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 2003, 3:304-316.
10. Lucas M., et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
11. Fehniger T.A., et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007, 26:798-811.
12. Kang S.J., et al. Regulation of hierarchical clustering and activation of innate immune cells by dendritic cells. Immunity 2008, 29:819-833.
13. Gidlund M., et al. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978, 273:759-761.
14. Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 1998, 16:359-393.
15. Yokoyama W.M. Natural killer cell receptors. Curr. Opin. Immunol. 1998, 10:298-305.
16. Hart O.M., et al. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol. 2005, 175:1636-1642.
17. Schmidt K.N., et al. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 2004, 172:138-143.
18. Yokoyama W.M., Seaman W.E. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu. Rev. Immunol. 1993, 11:613-635.
19. Moretta A., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 1996, 14:619-648.
20. Orr M.T., Lanier L.L. Natural killer cell education and tolerance. Cell 2010, 142:847-856.
21. Pegram H.J., et al. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 2011, 89:216-224.
22. Bakker A.B., et al. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum. Immunol. 2000, 61:18-27.
23. Long E.O., Rajagopalan S. Stress signals activate natural killer cells. J. Exp. Med. 2002, 196:1399-1402.
24. Beuneu H., et al. Dynamic behavior of NK cells during activation in lymph nodes. Blood 2009, 114:3227-3234.
25. Bajenoff M., et al. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J. Exp. Med. 2006, 203:619-631.
26. Biron C.A., et al. Function and regulation of natural killer (NK) cells during viral infections: characterization of responses in vivo. Methods 1996, 9:379-393.
27. Mempel T.R., et al. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004, 427:154-159.
28. Yuan D. Interactions between NK cells and B lymphocytes. Adv. Immunol. 2004, 84:1-42.
29. Gerosa F., et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195:327-333.
30. Piccioli D., et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 2002, 195:335-341.
31. Mocikat R., et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569.
32. Adam C., et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005, 106:338-344.
33. Iyoda T., et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002, 195:1289-1302.
34. Krebs P., et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 2009, 113:6593-6602.
35. Frebel H., et al. How chronic viral infections impact on antigen-specific T-cell responses. Eur. J. Immunol. 2010, 40:654-663.
36. Biron C.A., et al. Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr. Top. Microbiol. Immunol. 2002, 263:7-27.
37. Cook K.D., Whitmire J.K. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J. Immunol. 2013, 190:641-649.
38. Andrews D.M., et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J. Exp. Med. 2010, 207:1333-1343.
39. Hayakawa Y., et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 2004, 172:123-129.
40. Joffre O.P., et al. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 2012, 12:557-569.
41. Medema J.P., et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 2001, 194:657-667.
42. Mandaric S., et al. IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. PLoS Pathog. 2012, 8:e1002846.
43. Agaugue S., et al. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008, 112:1776-1783.
44. Bachanova V., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014, 123:3855-3863.
45. Lee S.H., et al. Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J. Immunol. 2012, 189:2712-2716.
46. Martin-Fontecha A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 2004, 5:1260-1265.
47. Morandi B., et al. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur. J. Immunol. 2006, 36:2394-2400.
48. Laouar Y., et al. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 2005, 6:600-607.
49. Lee S.H., et al. Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J. Exp. Med. 2009, 206:2235-2251.
50. Perona-Wright G., et al. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe 2009, 6:503-512.
51. Richter K., et al. Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog. 2013, 9:e1003735.
52. Rabinovich B.A., et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 2003, 170:3572-3576.
53. Cerboni C., et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007, 110:606-615.
54. Lu L., et al. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007, 26:593-604.
55. Soderquest K., et al. Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J. Immunol. 2011, 186:3304-3308.
56. Waggoner S.N., et al. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 2010, 120:1925-1938.
57. Waggoner S.N., et al. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012, 481:394-398.
58. Lang P.A., et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:1210-1215.
59. Peppa D., et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 2013, 210:99-114.
60. Crouse J., et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 2014, 40:961-973.
61. Xu H.C., et al. Type I interferon protects antiviral CD8(+) T cells from NK cell cytotoxicity. Immunity 2014, 40:949-960.
62. Su H.C., et al. NK cell functions restrain T cell responses during viral infections. Eur. J. Immunol. 2001, 31:3048-3055.
63. Schuster I.S., et al. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. Immunity 2014, 41:646-656.
64. Roy S., et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 2008, 180:1729-1736.
65. Dhiman R., et al. NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. J. Immunol. 2012, 189:897-905.
66. Peng H., et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J. Clin. Invest. 2013, 123:1444-1456.
67. Min-Oo G., et al. Natural killer cells: walking three paths down memory lane. Trends Immunol. 2013, 34:251-258.
68. Paust S., von Andrian U.H. Natural killer cell memory. Nat. Immunol. 2011, 12:500-508.
69. Crome S.Q., et al. Natural killer cells regulate diverse T cell responses. Trends Immunol. 2013, 34:342-349.
70. Nausch N., Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008, 27:5944-5958.
71. MacIver N.J., et al. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 2013, 31:259-283.
72. Pearce E.L. Metabolism in T cell activation and differentiation. Curr. Opin. Immunol. 2010, 22:314-320.
73. Ruggeri L., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
74. Shlomchik W.D., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
75. Olson J.A., et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010, 115:4293-4301.
76. Cornberg M., et al. Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response. Front. Immunol. 2013, 4:475.
77. Zhang B., et al. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.
78. Bielekova B., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5941-5946.
79. Brod S.A., Burns D.K. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 1994, 44:1144-1148.
80. Ann Marrie R., Rudick R.A. Drug Insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2:34-44.
81. Favara B.E. Hemophagocytic lymphohistiocytosis: a hemophagocytic syndrome. Semin. Diagn. Pathol. 1992, 9:63-74.
82. Stepp S.E., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286:1957-1959.
83. Kogawa K., et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002, 99:61-66.
84. Jordan M.B., et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104:735-743.
85. Sullivan K.E., et al. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr. Res. 1998, 44:465-468.
86. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
87. Fernandez N.C., et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
88. Hoglund P., et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m-mice: nonresponsiveness controlled by beta 2m-bone marrow in chimeric mice. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10332-10336.
89. Liao N.S., et al. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991, 253:199-202.
90. Wiemann K., et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 2005, 175:720-729.
91. Sun J.C., Lanier L.L. Tolerance of NK cells encountering their viral ligand during development. J. Exp. Med. 2008, 205:1819-1828.
92. Tripathy S.K., et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J. Exp. Med. 2008, 205:1829-1841.
93. Hoglund P., Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat. Rev. Immunol. 2010, 10:724-734.
94. Brodin P., et al. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol. 2009, 30:143-149.
95. Brodin P., et al. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009, 113:2434-2441.
96. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
97. Jamieson A.M., et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17:19-29.
98. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003, 3:781-790.
99. Mandelboim O., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
100. Hudspeth K., et al. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front. Immunol. 2013, 4:69.